President Trump’s executive order on essential medicines aims to encourage pharmaceutical companies to bring their manufacturing back to the U.S. But it may also have unintended consequences for both domestic and foreign companies.
Please log-in or register to access Engage and set your preferences
Create a free account for access to this publication and our vast catalogue of legal updates
Log-in to continue reading
Scan this QR Code to share this content
